
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health Co. demonstrated a positive financial trajectory with 4Q23 revenue reaching $96.8 million, surpassing both previous estimates of $95.2 million and $88.0 million, indicating strong demand and effective consumption management. The total systems average selling price (ASP) experienced a notable increase of approximately 20% quarter-over-quarter, rising to $28.8K, which was significantly ahead of prior expectations, reflecting an improved channel mix favoring direct sales. Despite the company's EBITDA guidance being back-end weighted, the strong performance in revenue and ASP suggests robust business fundamentals that position Beauty Health favorably for future growth.
Bears say
Beauty Health's stock outlook is negatively impacted by a significant decline in core delivery system placements, which fell over 30% year-over-year and quarter-over-quarter, totaling 1,210 units, and significantly below expectations. The deceleration in new system placements raises concerns about future consumable sales, which are critical for achieving management's profitability goals in 2024. Additionally, management's sales and adjusted EBITDA guidance for the first quarter of 2024 is notably below prior estimates, creating a reliance on an unprecedented increase in EBITDA margins in the second half of the year to meet full-year targets.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares